Protagonist Therapeutics Inc (PTGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.55B
Last updated: Nov 17, 2026 at 11:06 AM ET
Protagonist Therapeutics Inc (PTGX) Financials: Revenue, Profit and Cash Flow
Protagonist Therapeutics reported revenue of $46.02M for the fiscal year ended Dec 31, 2025, down 89.4% from the year before. That year, net income was -$130.15M with a net margin of -282.8%, operating cash flow was $57.67M and free cash flow was $56.08M. The quarter ended Sep 30, 2026 had revenue of $274.41M and net income of $220.01M.
Revenue and Margins
Over the 8 years to Dec 2025, revenue grew from $20.06M, a compound annual rate of 10.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $46.02M | -89.4% | 100.0% | -343.6% | -282.8% |
| Dec 2024 | $434.43M | +624.1% | 100.0% | 58.2% | 63.3% |
| Dec 2023 | $60.00M | +125.7% | 100.0% | -156.1% | -131.6% |
| Dec 2022 | $26.58M | -2.8% | 100.0% | -494.2% | -479.3% |
| Dec 2021 | $27.36M | -4.4% | 100.0% | -460.0% | -458.9% |
| Dec 2020 | $28.63M | +12293.1% | 100.0% | -225.4% | -231.1% |
| Dec 2019 | $231.00K | -99.3% | 100.0% | -34857.6% | -33414.3% |
| Dec 2018 | $30.93M | +54.1% | 100.0% | -136.7% | -125.9% |
| Dec 2017 | $20.06M | N/A | 100.0% | -188.9% | -184.2% |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M | $28.63M | $231.00K | $30.93M | $20.06M | $0 |
| Gross profit | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M | $28.63M | $231.00K | $30.93M | $20.06M | $0 |
| Research and development | $159.29M | $138.13M | $120.16M | $126.22M | $126.01M | $74.51M | $65.00M | $59.50M | $46.18M | $25.70M |
| Operating income | -$158.13M | $252.84M | -$93.65M | -$131.37M | -$125.84M | -$64.52M | -$80.52M | -$42.27M | -$37.90M | -$32.67M |
| Net income | -$130.15M | $275.19M | -$78.95M | -$127.39M | -$125.55M | -$66.15M | -$77.19M | -$38.92M | -$36.96M | -$37.18M |
| EBITDA | N/A | N/A | N/A | -$128.63M | -$121.39M | -$61.80M | -$78.59M | -$41.56M | -$36.81M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $274.41M | $213.47M | $56.37M | $7.44M | $4.71M | $5.55M | $28.32M | $170.64M | $4.67M | $4.17M | $254.95M | $60.00M |
| Gross profit | $273.31M | $213.47M | $56.37M | $7.44M | $4.71M | $5.55M | $28.32M | $170.64M | $4.67M | $4.17M | $254.95M | $60.00M |
| Operating income | $218.33M | $158.77M | -$3.65M | -$50.35M | -$46.42M | -$42.04M | -$19.31M | $126.78M | -$41.45M | -$38.79M | $206.31M | $23.05M |
| Net income | $220.01M | $162.85M | $3.78M | -$44.38M | -$39.34M | -$34.77M | -$11.65M | $131.67M | -$33.21M | -$30.62M | $207.34M | $27.34M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $2.28M by $126.11M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $668.19M | $744.73M | $357.95M | $247.93M | $347.69M | $324.47M | $154.92M | $139.47M | $163.73M | $93.99M |
| Current assets | $577.57M | $591.64M | $355.58M | $243.08M | $340.74M | $315.61M | $145.31M | $137.50M | $150.95M | $83.24M |
| Cash and equivalents | $128.39M | $97.25M | $186.73M | $125.74M | $123.67M | $117.36M | $33.01M | $82.23M | $106.03M | $21.08M |
| Total liabilities | $53.48M | $69.43M | $21.27M | $32.32M | $47.67M | $44.86M | $74.95M | $26.96M | $43.10M | $6.43M |
| Short-term debt | $2.28M | $510.00K | $1.14M | $2.52M | $2.20M | $1.46M | $1.26M | $1.06M | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $0 | $9.79M | N/A | $0 | $0 |
| Shareholder equity | $614.71M | $675.29M | $336.68M | $215.61M | $300.02M | $279.61M | $79.96M | $112.52M | $120.63M | $87.56M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.15B | $885.54M | $697.46M | $669.89M | $701.69M | $718.01M | $742.13M | $744.73M | $603.86M | $614.63M | $629.28M | $357.95M |
| Total liabilities | $61.64M | $44.00M | $41.99M | $55.19M | $56.25M | $49.99M | $53.08M | $69.43M | $71.94M | $73.31M | $68.83M | $21.27M |
| Cash and equivalents | $498.30M | $420.08M | $193.71M | $128.39M | $113.71M | $168.54M | $139.65M | $97.25M | $131.12M | $355.64M | $172.57M | $186.73M |
| Shareholder equity | $1.08B | $841.54M | $655.47M | $614.71M | $645.44M | $668.02M | $689.05M | $675.29M | $531.91M | $541.32M | $560.44M | $336.68M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 97.2% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $57.67M | $184.15M | -$70.24M | -$108.14M | -$107.86M | -$72.48M | -$41.53M | -$49.95M | $3.87M | -$29.97M |
| Capital expenditures | $1.59M | $1.35M | $609.00K | $795.00K | $1.10M | $471.00K | $967.00K | $486.00K | $666.00K | $347.00K |
| Free cash flow | $56.08M | $182.80M | -$70.84M | -$108.93M | -$108.97M | -$72.95M | -$42.49M | -$50.43M | $3.21M | -$30.32M |
| Investing cash flow | -$49.33M | -$299.48M | -$39.26M | $91.47M | -$15.86M | -$90.97M | -$53.71M | $2.21M | $15.82M | -$59.33M |
| Financing cash flow | $22.86M | $25.85M | $170.48M | $18.84M | $129.92M | $247.63M | $46.04M | $24.11M | $65.55M | $106.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.22M | $219.05M | -$48.94M | -$36.98M | -$1.94M | -$28.78M | $125.36M | -$29.18M | -$27.86M | $268.62M | -$27.43M | $16.96M |
| Capital expenditures | $237.00K | $168.00K | $215.00K | $144.00K | $88.00K | $813.00K | $545.00K | $310.00K | $775.00K | $28.00K | $242.00K | $19.00K |
| Free cash flow | -$23.46M | $218.88M | -$49.16M | -$37.12M | -$2.02M | -$29.59M | $124.82M | -$29.49M | -$28.64M | $268.59M | -$27.67M | $16.94M |
Frequently Asked Questions About PTGX
What is Protagonist Therapeutics' annual revenue?
Protagonist Therapeutics reported revenue of $46.02M for the fiscal year ended Dec 31, 2025.
How fast is Protagonist Therapeutics' revenue growing?
Revenue was down 89.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.1%.
Is Protagonist Therapeutics profitable?
No. Protagonist Therapeutics reported net income of -$130.15M for the fiscal year ended Dec 31, 2025, with a net margin of -282.8%.
How much free cash flow does PTGX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $57.67M minus capital expenditures of $1.59M produced free cash flow of $56.08M.
How much debt does Protagonist Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $2.28M and cash and equivalents of $128.39M.
PTGX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors